|Antiinflammatory therapy with canakinumab for atherosclerotic disease|
PM Ridker, BM Everett, T Thuren, JG MacFadyen, WH Chang, ...
New England journal of medicine 377 (12), 1119-1131, 2017
|Rosuvastatin in older patients with systolic heart failure|
J Kjekshus, E Apetrei, V Barrios, M Böhm, JGF Cleland, JH Cornel, ...
New England Journal of Medicine 357 (22), 2248-2261, 2007
|Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study|
Lancet 349, 1429-1435, 1997
|Apixaban with antiplatelet therapy after acute coronary syndrome|
JH Alexander, RD Lopes, S James, R Kilaru, Y He, P Mohan, DL Bhatt, ...
New England Journal of Medicine 365 (8), 699-708, 2011
|Lenient versus strict rate control in patients with atrial fibrillation|
IC Van Gelder, HF Groenveld, HJGM Crijns, YS Tuininga, JGP Tijssen, ...
New England Journal of Medicine 362 (15), 1363-1373, 2010
|Renal function as a predictor of outcome in a broad spectrum of patients with heart failure|
HL Hillege, D Nitsch, MA Pfeffer, K Swedberg, JJV McMurray, S Yusuf, ...
Circulation 113 (5), 671-678, 2006
|Prasugrel versus clopidogrel for acute coronary syndromes without revascularization|
MT Roe, PW Armstrong, KAA Fox, HD White, D Prabhakaran, ...
New England Journal of Medicine 367 (14), 1297-1309, 2012
|Thrombin-receptor antagonist vorapaxar in acute coronary syndromes|
P Tricoci, Z Huang, C Held, DJ Moliterno, PW Armstrong, F Van de Werf, ...
New England Journal of Medicine 366 (1), 20-33, 2012
|Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary …|
JJ Bax, W Wijns, JH Cornel, FC Visser, E Boersma, PM Fioretti
Journal of the American College of Cardiology 30 (6), 1451-1460, 1997
|Early invasive versus selectively invasive management for acute coronary syndromes|
RJ de Winter, F Windhausen, JH Cornel, PHJM Dunselman, CL Janus, ...
New England Journal of Medicine 353 (11), 1095-1104, 2005
|Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial|
SJ Nicholls, R Puri, T Anderson, CM Ballantyne, L Cho, JJP Kastelein, ...
Jama 316 (22), 2373-2384, 2016
|Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo …|
PM Ridker, JG MacFadyen, T Thuren, BM Everett, P Libby, RJ Glynn, ...
The Lancet 390 (10105), 1833-1842, 2017
|Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial|
AF Hernandez, JB Green, S Janmohamed, RB D'Agostino Sr, CB Granger, ...
The Lancet 392 (10157), 1519-1529, 2018
|Prediction of improvement of regional left ventricular function after surgical revascularization: a comparison of low-dose dobutamine echocardiography with 201Tl single-photon …|
M Arnese, JH Cornel, A Salustri, APWM Maat, A Elhendy, AEM Reijs, ...
Circulation 91 (11), 2748-2752, 1995
|Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial|
S James, DJ Angiolillo, JH Cornel, D Erlinge, S Husted, F Kontny, J Maya, ...
European heart journal 31 (24), 3006-3016, 2010
|Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable …|
JJ Bax, D Poldermans, A Elhendy, JH Cornel, E Boersma, R Rambaldi, ...
Journal of the American College of Cardiology 34 (1), 163-169, 1999
|Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled …|
PM Ridker, JG MacFadyen, BM Everett, P Libby, T Thuren, RJ Glynn, ...
The Lancet 391 (10118), 319-328, 2018
S James, A Budaj, P Aylward, KK Buck, CP Cannon, JH Cornel, ...
Circulation 122 (11), 1056-1067, 2010
|Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial|
RC Becker, JP Bassand, A Budaj, DM Wojdyla, SK James, JH Cornel, ...
European heart journal 32 (23), 2933-2944, 2011
|Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and …|
SK James, MT Roe, CP Cannon, JH Cornel, J Horrow, S Husted, H Katus, ...
Bmj 342, 2011